DK1606233T3 - Phospholipidestere af Clofarabin - Google Patents

Phospholipidestere af Clofarabin

Info

Publication number
DK1606233T3
DK1606233T3 DK04721537T DK04721537T DK1606233T3 DK 1606233 T3 DK1606233 T3 DK 1606233T3 DK 04721537 T DK04721537 T DK 04721537T DK 04721537 T DK04721537 T DK 04721537T DK 1606233 T3 DK1606233 T3 DK 1606233T3
Authority
DK
Denmark
Prior art keywords
clofarabine
phospholipid esters
phospholipid
esters
lipidesters
Prior art date
Application number
DK04721537T
Other languages
English (en)
Inventor
Dieter Herrmann
Robert Voigt
William E Bauta
Birgit Heckl-Oestreicher
Christoph Mueller
Christian Lutz
Original Assignee
Heidelberg Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heidelberg Pharma Gmbh filed Critical Heidelberg Pharma Gmbh
Application granted granted Critical
Publication of DK1606233T3 publication Critical patent/DK1606233T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Fats And Perfumes (AREA)
DK04721537T 2003-03-19 2004-03-18 Phospholipidestere af Clofarabin DK1606233T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45600303P 2003-03-19 2003-03-19
EP03006059A EP1460082A1 (en) 2003-03-19 2003-03-19 Phospholipid esters of clofarabine derivatives

Publications (1)

Publication Number Publication Date
DK1606233T3 true DK1606233T3 (da) 2006-09-18

Family

ID=33031244

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04721537T DK1606233T3 (da) 2003-03-19 2004-03-18 Phospholipidestere af Clofarabin

Country Status (21)

Country Link
US (1) US7419965B2 (da)
EP (2) EP1460082A1 (da)
JP (1) JP2006520359A (da)
KR (1) KR20050109939A (da)
CN (1) CN100369926C (da)
AT (1) ATE328000T1 (da)
AU (1) AU2004222163A1 (da)
CA (1) CA2519434A1 (da)
CY (1) CY1105572T1 (da)
DE (1) DE602004001047T2 (da)
DK (1) DK1606233T3 (da)
ES (1) ES2265636T3 (da)
MX (1) MXPA05008817A (da)
NO (1) NO20053903L (da)
NZ (1) NZ542011A (da)
PL (1) PL1606233T3 (da)
PT (1) PT1606233E (da)
RU (1) RU2347786C2 (da)
SI (1) SI1606233T1 (da)
WO (1) WO2004083155A2 (da)
ZA (1) ZA200507541B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2070938A1 (en) * 2007-12-13 2009-06-17 Heidelberg Pharma AG Clofarabine dietherphospholipid derivatives
CN102079766A (zh) * 2009-11-29 2011-06-01 海南中化联合制药工业股份有限公司 一种单磷酸阿糖腺苷的制备方法
CN101709073B (zh) * 2009-12-01 2013-01-23 北京大学 核苷酸磷脂分子及脂质体及其制备方法和应用
CN103232510B (zh) * 2012-11-23 2015-12-23 北京大学 5’-氨基-2’,5’-双脱氧核苷酸磷脂分子及其制备方法和应用
US9771385B2 (en) * 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
KR102371969B1 (ko) 2016-12-23 2022-03-08 주식회사 엘지에너지솔루션 배터리 모듈
JP7465416B2 (ja) * 2018-06-26 2024-04-11 ティーエスアールエル インコーポレイテッド 代謝安定性プロドラッグ
WO2024059754A1 (en) * 2022-09-14 2024-03-21 Quantapore, Inc. Polythiolated linkers for stable nanoparticle suspensions and uses thereof
AU2024370164A1 (en) * 2023-10-29 2026-05-14 Maia Biotechnology, Inc. Telomere-targeting phosphatidyl-thio conjugates

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4751221A (en) 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
JPS6383094A (ja) * 1986-09-27 1988-04-13 Toyo Jozo Co Ltd エ−テル型ヌクレオシド−リン脂質複合体
DE4026265A1 (de) 1990-08-20 1992-02-27 Boehringer Mannheim Gmbh Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
US5512671A (en) * 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
DE4321978A1 (de) * 1993-07-01 1995-01-12 Boehringer Mannheim Gmbh Liponucleotide von Desoxynucleosiden, deren Herstellung sowie deren Verwendung als antivirale Arzneimittel
AU711367B2 (en) * 1994-11-12 1999-10-14 Heidelberg Pharma Holding Gmbh Lipid-splitting enzyme
US7517858B1 (en) * 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
US7026469B2 (en) * 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
US6670341B1 (en) * 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells

Also Published As

Publication number Publication date
NO20053903L (no) 2005-12-19
EP1460082A1 (en) 2004-09-22
ATE328000T1 (de) 2006-06-15
EP1606233A2 (en) 2005-12-21
CA2519434A1 (en) 2004-09-30
PT1606233E (pt) 2006-09-29
WO2004083155A2 (en) 2004-09-30
NZ542011A (en) 2008-02-29
DE602004001047T2 (de) 2007-04-19
CN100369926C (zh) 2008-02-20
NO20053903D0 (no) 2005-08-22
RU2347786C2 (ru) 2009-02-27
EP1606233B1 (en) 2006-05-31
SI1606233T1 (sl) 2006-10-31
AU2004222163A1 (en) 2004-09-30
DE602004001047D1 (de) 2006-07-06
WO2004083155A3 (en) 2005-03-31
RU2005130992A (ru) 2006-04-10
US7419965B2 (en) 2008-09-02
CY1105572T1 (el) 2010-07-28
KR20050109939A (ko) 2005-11-22
US20060293514A1 (en) 2006-12-28
ZA200507541B (en) 2006-05-31
CN1771253A (zh) 2006-05-10
PL1606233T3 (pl) 2006-10-31
MXPA05008817A (es) 2005-10-18
JP2006520359A (ja) 2006-09-07
ES2265636T3 (es) 2007-02-16

Similar Documents

Publication Publication Date Title
CY1120384T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
CY1115059T1 (el) Θεραπευτικα απταμερη χρησιμα στην θεραπευτικη αγωγη διαταραχων σχετιζομενων με συμπληρωμα
BR0315689A (pt) Alvo para terapia de dano cognitivo
TW200612918A (en) Lonidamine analogs
DE602004020901D1 (de) System zur Einführung von mehreren Medizinprodukten
ATE471334T1 (de) Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
CY1113094T1 (el) Ανοσοσφαιρινες κατευθυνομενες εναντι nogo
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
DK1503788T3 (da) Behandling af alpha-galactosidase A-deficiens
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
EP1787571A4 (en) SOURCE OF LIGHT AND ENDOSCOPE EQUIPPED WITH THIS SOURCE OF LIGHT
DE60328476D1 (de) Medizinisches ballonsystem zur behandlung von adipositas
DK1729824T3 (da) Phospholipidanaloger til behandling af cancere
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
CY1110043T1 (el) 2-αμινοβενζουλ παραγωγα
SE0301650D0 (sv) Novel compounds
BRPI0509660A (pt) compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias
DE602004001047D1 (de) Phospholipidester von Clofarabin
DE60325194D1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
DE602004005821D1 (de) Enteralpräparat zur vorbeugung gegen bzw. behandlung von sepsis
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit